Covid-19 Vaccines in Development and Use

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a positive sense, single-stranded RNA beta coronavirus, a member of Beta-CoV lineage B (subgenus Sarbecovirus).

Here is a list of approved vaccines and vaccines in development. This data is for informational purposes only, not medical advice.

Table 1. Vaccines In Use

Candidate	Status/clinical trials	Sponsor/Producer	Number of countries vaccine being used	Efficacy, %
Vaxzevria (CoviShield) AZD1222 (ChAdOx1) Viral vector	Phase III NCT04516746 NCT04540393 Phase I/II NCT04568031 NCT04686773	AstraZeneca, University of Oxford	184	63.0 https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know
Comirnaty BNT162b2 mRNA vaccine	Phase III NCT04713553(completed) NCT04848584	BioNTech in collaboration with Pfizer	124	95.0 https://www.who.int/en/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine
Spikevax mRNA-1273 mRNA vaccine	Phase IIINCT04860297Phase IINCT04847050Phase I NCT04283461 NCT04785144	NIAID in collaboration with Moderna Therapeutics	71	94.1 https://www.who.int/publications/i/item/interim-recommendations-for-use-of-the-moderna-mrna-1273-vaccine-against-covid-19
BBIBP-CorV Inactivated virus	Phase I/II NCT04993560	Sinopharm-Beijing	68	86.0 https://gulfnews.com/uae/health/uae-ministry-of-health-announces-86-per-cent-vaccine-efficacy-1.1607490555571
JNJ-78436735 (Ad26.COV2.S)Viral vector	Phase III NCT04505722	Johnson & Johnson	48	66.9 https://www.who.int/news-room/feature-stories/detail/the-j-j-covid-19-vaccine-what-you-need-to-know
Sputnik V Gam-COVID-Vac, Gam-COVID-VacLyo Viral vector	Phase I/II clinical trial in Russia NCT04436471 NCT04437875 Phase III NCT04530396	Gamaleya Research Institute	46	94.0 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00234-8/fulltext
CoronaVac Inactivated virus	Phase III clinical trial in BrazilNCT04456595 Phase IV NCT04789356	Sinovac, ButantanInstitute	41	51
Covaxin BBV-152 Inactivated virus	Phase I/II NCT04471519 Phase III NCT04641481	Bharat Biotech	7	-
Recombinant Coronavirus vaccine	Phase II NCT04313127 NCT04341389	CanSino Biologics Inc.	5	-

Table 2. Vaccines in development

Candidate	Vaccine type	Status/clinical trials	Sponsor/Producer
AdimrSC-2f	protein subunit	Phase I Clinical Trials in Taiwan NCT04522089	Adimmune Corporation
siRNA	RNA	Preclinical development	Alnylam and Vir Biotechnology
ZF2001	protein subunit	Phase III	AnhuiZhifei Longcom
ARCT-021	RNA	Phase II NCT04728347	Arcturus Therapeutics
BBV-154	viral vector	Phase I NCT04751682	Bharat Biotech
SCB-2019	protein subunit	Phase I NCT04932824	Clover Biopharmaceuticals
COVI-VAC	live-attenuated	Phase I NCT04619628	Codagenix
UB-612	multitope peptide-based vaccine (MPV)	Phase I NCT04545749	COVAXX, United Biomedical
CVnCoV	mRNA	Phase III NCT04860258	Curevac
Vaccine adjuvant CpG1018		Phase III NCT05012787	Dynavax Technologies Corp
Coronavirus vaccine		Preclinical development	Geovax
Vaccine adjuvant		Preclinical development (adjuvant to S-Trimer vaccine)	GlaxoSmithKline
Self-assembling vaccine (SAV)		Preclinical development	HaloVax (Hoth Therapeutics + Voltron Therapeutics)
Coronavirus vaccine		Preclinical development	Heat Biologics Inc.
INO-4800 DNA-based vaccine	DNA	Phase I/II Clinical Trials NCT04447781 NCT04336410	Inovio Pharmaceuticals
ReCoV	protein subunit	Phase I	Jiangsu Rec-Biotechnology Co Ltd
MVC-COV1901	protein subunit	Phase I/II NCT04487210 NCT04951388	Medigen
mRNA-1283	mRNA	Phase I NCT04813796	NIAID in collaboration with Moderna Therapeutics
NVX-CoV2373 Coronavirus vaccine	protein subunit	Preclinical development	Novavax Inc
CoVepiT (OSE13E)	protein subunit	Phase I NCT04885361	OSE Immunotherapeutics
TAK-019 (Novavax formulation)	protein subunit	Phase I/II NCT04712110	Takeda
adjuvanted recombinant protein vaccine		Phase II/III NCT04762680	Sanofi Pasteur with GSK